Bradley Lether Pentelute

This inventor holds 29 USPTO granted patents and 23 published patent applications and 3 EPO patents, primarily in Peptide Synthesis. Top assignees: Massachusetts Institute of Technology, Harvard College, Sarepta Therapeutics, Inc.. Active years: 2015-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bradley Lether Pentelute. Retrieved from https://idiyas.com/inventor/bradley-lether-pentelute

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 29 (Patent Applications = 23)

% Patents Active = 100.0

EPO Patents = 3 (Patent Applications = 16)

Average Co-Inventor Count = 3.8

ph-index = 7

Forward Citations = 123(Granted Patents)

Location History:

Cambridge, MA (US) (2015 - 2024)
Revere, MA (US) (2024)

Company Filing History:

27 out of 8,594

Massachusetts Institute of Technology

Sarepta Therapeutics, Inc.

where one patent can have more than one assignee

Years Active: 2015-2026

Loading Chart...

Areas of Expertise:

Phosphorodiamidate Morpholino Oligomers

Bicyclic Peptide Oligonucleotide Conjugates

Chimeric Peptides

Cell-Penetrating Peptides

Solid Phase Peptide Synthesis

Himastatin Derivatives

Albumin Binding Peptide Conjugates

Pain Treatment Compositions

Protein Retrosplicing

Translocation of Chemical Entities

Cysteine Arylation

Affinity Selection

29 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12590306 - Processes for preparing phosphorodiamidate morpholino oligomers via fast-flow synthesis (2026-03-31),

2. 12502432 - BICYCLIC PEPTIDE OLIGONUCLEOTIDE CONJUGATES (2025-12-23),

3. 12370261 - Chimeric peptides for antisense delivery (2025-07-29),

4. 12168059 - Trimeric peptides for antisense delivery (2024-12-17),

5. 12138312 - Cell-penetrating peptides for antisense delivery (2024-11-12),

6. 12043646 - Methods and systems for solid phase peptide synthesis (2024-07-23),

7. 12030888 - Himastatin derivatives, and processes of preparation thereof, and uses thereof (2024-07-09),

8. 11878996 - Solid phase peptide synthesis processes and associated systems (2024-01-23),

9. 11753633 - Compositions and methods for treatment of pain (2023-09-12),

10. 11672869 - Functionalization of bacterial effector translocase protein by chemical conjugation (2023-06-13),

11. 11642416 - Albumin binding peptide conjugates and methods thereof (2023-05-09),

12. 11584776 - Methods and systems for solid phase peptide synthesis (2023-02-21),

13. 11279734 - Solution-phase affinity selection of inhibitors from combinatorial peptide libraries (2022-03-22),

14. 11104892 - Compositions and methods for treatment of pain (2021-08-31),

15. 11077199 - Albumin binding peptide conjugates and methods thereof (2021-08-03),

Title: The Innovative Mind of Bradley Lether Pentelute: A Pioneer in Antisense Delivery

Introduction: Bradley Lether Pentelute, based in Cambridge, MA, is a distinguished inventor with a notable track record of 26 patents. His innovative work primarily focuses on the development of novel peptide-based strategies for the delivery of therapeutic oligonucleotides. Pentelute's research has made significant contributions to the fields of molecular biology and medicine, particularly in addressing muscle diseases and infections.

Latest Patents: Among Pentelute's latest patents are groundbreaking advancements in the realm of antisense delivery. One such patent, titled “Trimeric peptides for antisense delivery,” describes a range of oligonucleotides, trimeric peptides, and peptide-oligonucleotide conjugates. This innovation is aimed at treating muscle diseases by administering these peptides and oligonucleotides to affected individuals. Another significant patent is focused on “Cell-penetrating peptides for antisense delivery,” which outlines oligonucleotides, cell-penetrating peptides, and peptide-oligonucleotide conjugates designed to combat muscle diseases as well as viral and bacterial infections.

Career Highlights: During his career, Pentelute has collaborated with prestigious institutions such as the Massachusetts Institute of Technology (MIT) and the President and Fellows of Harvard College. His work at these renowned institutions has been pivotal in advancing the understanding of peptide-based drug delivery systems, enabling targeted therapies that can significantly improve patient outcomes.

Collaborations: Pentelute has closely worked with prominent researchers, including Mark David Simon and Andrea Adamo. Their collaborative efforts have contributed to the development of innovative solutions in the treatment of various medical conditions, enhancing the field's overall knowledge and technological capabilities.

Conclusion: Bradley Lether Pentelute is an exemplary inventor whose contributions to antisense delivery and molecular therapeutics are commendable. With a strong patent portfolio and collaborations with leading research institutions, his work continues to inspire advancements in medical science, promising improved therapies for challenging health conditions. Pentelute's innovative spirit exemplifies the impact of dedicated research in transforming theoretical concepts into tangible medical applications.

Profile summary based on public USPTO records.